A 30-year-old male presented with fever, abdominal distension, and a white blood cell (WBC) count of 101,700/mm^3^. A bone marrow immunophenotyping study showed about 91% of marrow nucleated cells were lymphoblasts expressing CD45, CD10, Cd2, sCD3, CD4, CD5, and CD7, which was consistent with acute T-lymphoblastic leukemia/lymphoma (T-ALL), medullary type. The patient had a normal karyotype but fluorescence *in situ* hybridization study revealed *CDKN2A* 9p21 deletion. At diagnosis, he had no respiratory symptom and chest X-ray (CXR) findings were normal. On day 7 of induction chemotherapy, which was composed of vincristine, prednisolone, daunorubicin, and L-asparaginase, he complained of a cough and right pleuritic chest pain with fever. Despite the use of broad-spectrum antibiotics, the fever persisted, and on day 12, CXR depicted peribronchial consolidation. His symptoms then rapidly aggravated. On day 15, his PaO~2~ was 53 mmHg with a FiO~2~ of 0.8 by a reservoir mask, and his laboratory results were as follows: hemoglobin 8.3 g/dL, WBCs 840/mm^3^ (absolute neutrophil count \[ANC\] 250/mm^3^), and platelets 102,000/mm^3^; renal and hepatic functions were normal. Due to uncorrectable and progressing hypoxemia, mechanical ventilation after endotracheal intubation was decided. A positive result for *Legionella* urinary antigen raised the possibility of *Legionella* pneumonia, although no microorganism was reported by culture of any body fluid or by molecular testing for a respiratory infection. Intensive efforts, including escalation of antimicrobial agents and prone positioning, were then taken. However, he failed to maintain a PaO~2~ of ≥ 60 mmHg with a FiO~2~ of 1.0. On day 18, veno-venous extracorporeal membrane oxygenation (ECMO) support was decided; at that time, he had no impairment of cardiac, renal, or hepatic function. Five days later, he escaped from severe neutropenia (ANC \< 500/mm^3^), and CXRs showed gradual improvement ([Fig. 1](#f1-kjim-2016-260){ref-type="fig"}). ECMO was removed on day 36 and on day 50, complete remission of T-ALL was confirmed by bone marrow study and he discharged from hospital. Subsequently, he underwent consolidative chemotherapy and at the time of writing, over 28 months after diagnosis, was surviving.

Kang et al. \[[@b1-kjim-2016-260]\] reported outcomes of ECMO in 15 patients with hematologic malignancies (HMs). This study is valuable because few reports have been issued on ECMO in patients with HM, which are a profoundly immunosuppressed population, but with the possibility of cure. Because all 15 patients died in this previous study, negative impressions are inevitable with regard to ECMO in patients with HM. However, our patient shows potential benefit of ECMO in patients with HM can be realized if patients are adequately selected \[[@b2-kjim-2016-260],[@b3-kjim-2016-260]\]. Wohlfarth et al. \[[@b4-kjim-2016-260]\] conducted a retrospective analysis of 14 Austrian patients with HM that received ECMO and reported more optimistic outcomes; seven achieved long-term disease-free survival. A comparison of patient characteristics in these two previous studies suggests reasons for the survival difference (0% vs. 50%). First, the Korean patients were older (mean 46 ± 13.6 years) than the Austrian patients (median 32; range, 21 to 51). Second, the types of HM included were fundamentally different. In the Korean study, nine patients had acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS), and only one patient had Hodgkin lymphoma. On the other hand, in the Austrian study, eight patients had lymphoma and only one patient had AML. Thus, it appears the inclusion of younger patients and more patients with malignant lymphoma, which are indicators of better survival than AML/MDS, may have contributed to this difference. It might be due to the difference of the intensity of chemotherapy (i.e., high dose chemotherapy for AML or ALL, leading to several weeks of myelosuppression vs. chemotherapy for lymphoma such as CHOP \[cyclophosphamide, doxorubicin, vincristine, and prednisone\] regimen leading to only several days of neutropenia), rather than type of HM per se. One feature shared by these two studies is that patients with ECMO after allogenic stem cell transplantation (allo-SCT) showed extremely poor outcomes; seven Korean and four Austrian patients received ECMO after allo-SCT, and none survived \[[@b1-kjim-2016-260],[@b4-kjim-2016-260]\]. The poor outcomes may have been due to a profound immunosuppression. Although the Extracorporeal Life Support Organization (ELSO) guideline suggests major pharmacologic immunosuppression (ANC \< 400 mm^3^) is a contraindication \[[@b5-kjim-2016-260]\], we decided to apply ECMO because we expected that the duration of neutropenia would be limited, and therefore, there was some likelihood of improvement. Based on our experience, we suggest the expected duration of immunosuppression should be taken into account when considering ECMO.

Future studies with larger number of patients in various types of HM with different disease severities are needed to define the role of ECMO more precisely.
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